There have been a number of activities in the BMSCTC during the past year. Using the Centers approved bone marrow acquisition protocol (10-CC-0053 - Collection of Bone Marrow from Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products, Stroncek, CC, PI), a bank of frozen BMSCs has been established for allogeneic use in a clinical protocol for the treatment of acute Graft Versus Host Disease (12-H-0010 - A Phase I Study of Bone Marrow Stromal Cell Infusions to Treat Acute Graft Versus Host Disease, Marrow Failure and Tissue Injury After Allogeneic Stem Cell Transplantation, Battiwalla and Barrett, NHLBI, PIs). This trial is in follow-up and data are under analysis. The allogeneic cells are also being used in a trial to treat inflammatory bowel disease (13-I-0077 - An Open-Label, Phase 1 Study to Assess the Safety and Tolerability of Bone Marrow Stromal Cell Infusion for the treatment of Moderate to Severe Inflammatory Bowel Disease, Yao, NIAID, PI), which has just started patient accrual. Autologous cells were generated for direct use (no freezing) in patients under going coronary artery bypass grafting and trans myocardial laser revascularization (12-H-0078 - Preliminary Assessment of Direct Intra-Myocardial Injection of Autologous Bone Marrow-derived Stromal Cells on Patients Undergoing Revascularization for CAD with Depressed Left Ventricular Function, Robey, NIDCR, PI and Horvath, NHLBI, LAI). Two other clinical protocols for the treatment of osteonecrosis of the jaw (Shastry and Robey, NIDCR;Citrin and Landgren, NCI), and skull bone regeneration (Robey, NIDCR) are under preparation. In addition to preparing clinical grade BMSCs, the Center also has been developing techniques to better monitor their biological activity during ex vivo expansion. Such monitoring will improve the ability to qualify a particular lot of cells prior to their clinical use. Every cell lot under goes molecular profiling (microarray analysis and other methods). By having the transcriptomic signature of a particular lot, it may be possible to determine factors that were present in lots that were administered to patients that improved versus those that were administered to patients that did not improve. In addition, by studying the profile of the cells from different donors at different stages if in vitro aging, a list of 24 genes (12 that were up-regulated and twelve that were down-regulated) appeared to predict the age of the cells. It was also found that there is donor variability in the in vitro aging process (i.e., some donors cells at passage 5 had a similar signature as those from another donor at passage 10). This list of 24 genes may be useful in determining release criteria of future cell lots developed by the center.
|Yin, Fang; Battiwalla, Minoo; Ito, Sawa et al. (2014) Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses. Stem Cells 32:1278-88|
|Stroncek, David F; Sabatino, Marianna; Ren, Jiaqiang et al. (2014) Establishing a bone marrow stromal cell transplant program at the National Institutes of Health Clinical Center. Tissue Eng Part B Rev 20:200-5|
|Ren, Jiaqiang; Stroncek, David F; Zhao, Yingdong et al. (2013) Intra-subject variability in human bone marrow stromal cell (BMSC) replicative senescence: molecular changes associated with BMSC senescence. Stem Cell Res 11:1060-73|